nodes	percent_of_prediction	percent_of_DWPC	metapath
Mivacurium—BCHE—Irinotecan—lung cancer	0.107	0.551	CbGbCtD
Mivacurium—BCHE—Cisplatin—lung cancer	0.0869	0.449	CbGbCtD
Mivacurium—CHRND—pericardium—lung cancer	0.0526	0.446	CbGeAlD
Mivacurium—BCHE—diaphragm—lung cancer	0.0241	0.205	CbGeAlD
Mivacurium—Hypoxemia—Vinorelbine—lung cancer	0.0157	0.0497	CcSEcCtD
Mivacurium—Hypoxemia—Gemcitabine—lung cancer	0.0127	0.0399	CcSEcCtD
Mivacurium—CHRNA2—mammary gland—lung cancer	0.0104	0.0884	CbGeAlD
Mivacurium—CHRND—respiratory system—lung cancer	0.01	0.085	CbGeAlD
Mivacurium—Hypoxia—Gefitinib—lung cancer	0.00962	0.0304	CcSEcCtD
Mivacurium—Hypoxemia—Methotrexate—lung cancer	0.00647	0.0204	CcSEcCtD
Mivacurium—CHRND—lung—lung cancer	0.00532	0.0452	CbGeAlD
Mivacurium—Hypoxia—Vinorelbine—lung cancer	0.00497	0.0157	CcSEcCtD
Mivacurium—Phlebitis—Teniposide—lung cancer	0.0042	0.0133	CcSEcCtD
Mivacurium—Hypoxia—Gemcitabine—lung cancer	0.004	0.0126	CcSEcCtD
Mivacurium—Bradycardia—Crizotinib—lung cancer	0.00344	0.0109	CcSEcCtD
Mivacurium—Phlebitis—Vinblastine—lung cancer	0.0032	0.0101	CcSEcCtD
Mivacurium—Injection site reaction—Vinorelbine—lung cancer	0.00314	0.00992	CcSEcCtD
Mivacurium—Cardiac disorder—Crizotinib—lung cancer	0.00314	0.00991	CcSEcCtD
Mivacurium—Bronchospasm—Teniposide—lung cancer	0.00308	0.00971	CcSEcCtD
Mivacurium—Mediastinal disorder—Crizotinib—lung cancer	0.00305	0.00962	CcSEcCtD
Mivacurium—Arrhythmia—Crizotinib—lung cancer	0.00302	0.00954	CcSEcCtD
Mivacurium—Cardiac disorder—Gefitinib—lung cancer	0.00285	0.009	CcSEcCtD
Mivacurium—Angiopathy—Gefitinib—lung cancer	0.00279	0.0088	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Topotecan—lung cancer	0.00277	0.00875	CcSEcCtD
Mivacurium—Mediastinal disorder—Gefitinib—lung cancer	0.00277	0.00874	CcSEcCtD
Mivacurium—Arrhythmia—Pemetrexed—lung cancer	0.00276	0.00872	CcSEcCtD
Mivacurium—BCHE—respiratory system—lung cancer	0.00275	0.0234	CbGeAlD
Mivacurium—Arrhythmia—Gefitinib—lung cancer	0.00274	0.00866	CcSEcCtD
Mivacurium—Erythema—Pemetrexed—lung cancer	0.00269	0.00849	CcSEcCtD
Mivacurium—Phlebitis—Vinorelbine—lung cancer	0.00266	0.00841	CcSEcCtD
Mivacurium—Injection site reaction—Gemcitabine—lung cancer	0.00252	0.00797	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Crizotinib—lung cancer	0.00249	0.00786	CcSEcCtD
Mivacurium—CHRNB1—lymph node—lung cancer	0.00235	0.0199	CbGeAlD
Mivacurium—Skin disorder—Crizotinib—lung cancer	0.00233	0.00737	CcSEcCtD
Mivacurium—Flushing—Teniposide—lung cancer	0.00232	0.00733	CcSEcCtD
Mivacurium—Wheezing—Cisplatin—lung cancer	0.0023	0.00726	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Pemetrexed—lung cancer	0.00227	0.00718	CcSEcCtD
Mivacurium—BCHE—bronchus—lung cancer	0.00227	0.0192	CbGeAlD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Gefitinib—lung cancer	0.00226	0.00714	CcSEcCtD
Mivacurium—Arrhythmia—Teniposide—lung cancer	0.00224	0.00706	CcSEcCtD
Mivacurium—Anaphylactic shock—Pemetrexed—lung cancer	0.0022	0.00693	CcSEcCtD
Mivacurium—Skin disorder—Pemetrexed—lung cancer	0.00213	0.00673	CcSEcCtD
Mivacurium—Skin disorder—Gefitinib—lung cancer	0.00212	0.00669	CcSEcCtD
Mivacurium—Injection site reaction—Paclitaxel—lung cancer	0.00211	0.00667	CcSEcCtD
Mivacurium—Wheezing—Paclitaxel—lung cancer	0.00206	0.00652	CcSEcCtD
Mivacurium—Hypoxia—Methotrexate—lung cancer	0.00204	0.00645	CcSEcCtD
Mivacurium—Hypotension—Gefitinib—lung cancer	0.00204	0.00644	CcSEcCtD
Mivacurium—BCHE—trachea—lung cancer	0.00203	0.0173	CbGeAlD
Mivacurium—Phlebitis—Cisplatin—lung cancer	0.00199	0.0063	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Irinotecan—lung cancer	0.00195	0.00617	CcSEcCtD
Mivacurium—Bronchospasm—Vinorelbine—lung cancer	0.00195	0.00616	CcSEcCtD
Mivacurium—BCHE—cardiac atrium—lung cancer	0.00191	0.0162	CbGeAlD
Mivacurium—Anaphylactoid reaction—Gemcitabine—lung cancer	0.0019	0.00601	CcSEcCtD
Mivacurium—Phlebitis—Etoposide—lung cancer	0.00183	0.00577	CcSEcCtD
Mivacurium—Injection site reaction—Docetaxel—lung cancer	0.00179	0.00566	CcSEcCtD
Mivacurium—Phlebitis—Paclitaxel—lung cancer	0.00179	0.00566	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Cisplatin—lung cancer	0.00177	0.0056	CcSEcCtD
Mivacurium—Urticaria—Pemetrexed—lung cancer	0.00174	0.00551	CcSEcCtD
Mivacurium—Tachycardia—Teniposide—lung cancer	0.00174	0.00548	CcSEcCtD
Mivacurium—Urticaria—Gefitinib—lung cancer	0.00173	0.00547	CcSEcCtD
Mivacurium—Angiopathy—Topotecan—lung cancer	0.00168	0.00531	CcSEcCtD
Mivacurium—Immune system disorder—Topotecan—lung cancer	0.00168	0.00529	CcSEcCtD
Mivacurium—Mediastinal disorder—Topotecan—lung cancer	0.00167	0.00528	CcSEcCtD
Mivacurium—Hypotension—Teniposide—lung cancer	0.00166	0.00525	CcSEcCtD
Mivacurium—Mediastinal disorder—Erlotinib—lung cancer	0.00165	0.00522	CcSEcCtD
Mivacurium—Arrhythmia—Erlotinib—lung cancer	0.00164	0.00518	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Etoposide—lung cancer	0.00163	0.00513	CcSEcCtD
Mivacurium—BCHE—bone marrow—lung cancer	0.00161	0.0137	CbGeAlD
Mivacurium—Erythema—Erlotinib—lung cancer	0.0016	0.00505	CcSEcCtD
Mivacurium—Dizziness—Crizotinib—lung cancer	0.00159	0.00502	CcSEcCtD
Mivacurium—Bronchospasm—Gemcitabine—lung cancer	0.00157	0.00495	CcSEcCtD
Mivacurium—Muscle spasms—Topotecan—lung cancer	0.00155	0.0049	CcSEcCtD
Mivacurium—Phlebitis—Docetaxel—lung cancer	0.00152	0.00479	CcSEcCtD
Mivacurium—Rash—Crizotinib—lung cancer	0.00151	0.00478	CcSEcCtD
Mivacurium—Dermatitis—Crizotinib—lung cancer	0.00151	0.00478	CcSEcCtD
Mivacurium—Cardiac disorder—Vinorelbine—lung cancer	0.00147	0.00465	CcSEcCtD
Mivacurium—Flushing—Vinorelbine—lung cancer	0.00147	0.00465	CcSEcCtD
Mivacurium—BCHE—lung—lung cancer	0.00146	0.0124	CbGeAlD
Mivacurium—Dizziness—Pemetrexed—lung cancer	0.00145	0.00458	CcSEcCtD
Mivacurium—Angiopathy—Vinorelbine—lung cancer	0.00144	0.00455	CcSEcCtD
Mivacurium—Immune system disorder—Vinorelbine—lung cancer	0.00143	0.00453	CcSEcCtD
Mivacurium—Mediastinal disorder—Vinorelbine—lung cancer	0.00143	0.00452	CcSEcCtD
Mivacurium—Arrhythmia—Vinorelbine—lung cancer	0.00142	0.00448	CcSEcCtD
Mivacurium—Urticaria—Teniposide—lung cancer	0.00141	0.00446	CcSEcCtD
Mivacurium—Rash—Pemetrexed—lung cancer	0.00138	0.00437	CcSEcCtD
Mivacurium—Dermatitis—Pemetrexed—lung cancer	0.00138	0.00437	CcSEcCtD
Mivacurium—Erythema—Vinorelbine—lung cancer	0.00138	0.00436	CcSEcCtD
Mivacurium—Rash—Gefitinib—lung cancer	0.00138	0.00434	CcSEcCtD
Mivacurium—Dermatitis—Gefitinib—lung cancer	0.00137	0.00434	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Topotecan—lung cancer	0.00137	0.00431	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—lung cancer	0.00135	0.00427	CcSEcCtD
Mivacurium—Bronchospasm—Etoposide—lung cancer	0.00134	0.00422	CcSEcCtD
Mivacurium—Bradycardia—Irinotecan—lung cancer	0.00133	0.00421	CcSEcCtD
Mivacurium—Anaphylactic shock—Topotecan—lung cancer	0.00132	0.00416	CcSEcCtD
Mivacurium—Skin disorder—Topotecan—lung cancer	0.00128	0.00404	CcSEcCtD
Mivacurium—Skin disorder—Erlotinib—lung cancer	0.00127	0.004	CcSEcCtD
Mivacurium—Flushing—Irinotecan—lung cancer	0.00121	0.00384	CcSEcCtD
Mivacurium—Cardiac disorder—Irinotecan—lung cancer	0.00121	0.00384	CcSEcCtD
Mivacurium—Bradycardia—Cisplatin—lung cancer	0.00121	0.00382	CcSEcCtD
Mivacurium—Angiopathy—Irinotecan—lung cancer	0.00119	0.00375	CcSEcCtD
Mivacurium—Cardiac disorder—Gemcitabine—lung cancer	0.00118	0.00374	CcSEcCtD
Mivacurium—Immune system disorder—Irinotecan—lung cancer	0.00118	0.00373	CcSEcCtD
Mivacurium—Mediastinal disorder—Irinotecan—lung cancer	0.00118	0.00372	CcSEcCtD
Mivacurium—Arrhythmia—Irinotecan—lung cancer	0.00117	0.00369	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—lung cancer	0.00117	0.00369	CcSEcCtD
Mivacurium—Angiopathy—Gemcitabine—lung cancer	0.00116	0.00365	CcSEcCtD
Mivacurium—Immune system disorder—Gemcitabine—lung cancer	0.00115	0.00364	CcSEcCtD
Mivacurium—Mediastinal disorder—Gemcitabine—lung cancer	0.00115	0.00363	CcSEcCtD
Mivacurium—Arrhythmia—Gemcitabine—lung cancer	0.00114	0.0036	CcSEcCtD
Mivacurium—Anaphylactic shock—Vinorelbine—lung cancer	0.00113	0.00356	CcSEcCtD
Mivacurium—Rash—Teniposide—lung cancer	0.00112	0.00354	CcSEcCtD
Mivacurium—Dermatitis—Teniposide—lung cancer	0.00112	0.00354	CcSEcCtD
Mivacurium—Injection site reaction—Doxorubicin—lung cancer	0.00112	0.00353	CcSEcCtD
Mivacurium—Bronchospasm—Docetaxel—lung cancer	0.00111	0.00351	CcSEcCtD
Mivacurium—Erythema—Gemcitabine—lung cancer	0.00111	0.0035	CcSEcCtD
Mivacurium—Flushing—Cisplatin—lung cancer	0.0011	0.00348	CcSEcCtD
Mivacurium—Cardiac disorder—Cisplatin—lung cancer	0.0011	0.00348	CcSEcCtD
Mivacurium—Tachycardia—Vinorelbine—lung cancer	0.0011	0.00347	CcSEcCtD
Mivacurium—Muscle spasms—Irinotecan—lung cancer	0.0011	0.00346	CcSEcCtD
Mivacurium—Skin disorder—Vinorelbine—lung cancer	0.0011	0.00346	CcSEcCtD
Mivacurium—Bradycardia—Paclitaxel—lung cancer	0.00109	0.00343	CcSEcCtD
Mivacurium—Immune system disorder—Cisplatin—lung cancer	0.00107	0.00339	CcSEcCtD
Mivacurium—Mediastinal disorder—Cisplatin—lung cancer	0.00107	0.00338	CcSEcCtD
Mivacurium—Arrhythmia—Cisplatin—lung cancer	0.00106	0.00335	CcSEcCtD
Mivacurium—Hypotension—Vinorelbine—lung cancer	0.00105	0.00333	CcSEcCtD
Mivacurium—Urticaria—Topotecan—lung cancer	0.00105	0.00331	CcSEcCtD
Mivacurium—Erythema—Cisplatin—lung cancer	0.00103	0.00327	CcSEcCtD
Mivacurium—Flushing—Etoposide—lung cancer	0.00101	0.00319	CcSEcCtD
Mivacurium—Cardiac disorder—Etoposide—lung cancer	0.00101	0.00319	CcSEcCtD
Mivacurium—BCHE—lymph node—lung cancer	0.001	0.00848	CbGeAlD
Mivacurium—Muscle spasms—Cisplatin—lung cancer	0.000995	0.00314	CcSEcCtD
Mivacurium—Flushing—Paclitaxel—lung cancer	0.000991	0.00313	CcSEcCtD
Mivacurium—Cardiac disorder—Paclitaxel—lung cancer	0.000991	0.00313	CcSEcCtD
Mivacurium—Angiopathy—Etoposide—lung cancer	0.000988	0.00312	CcSEcCtD
Mivacurium—Immune system disorder—Etoposide—lung cancer	0.000983	0.0031	CcSEcCtD
Mivacurium—Mediastinal disorder—Etoposide—lung cancer	0.000981	0.0031	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Methotrexate—lung cancer	0.000974	0.00308	CcSEcCtD
Mivacurium—Angiopathy—Paclitaxel—lung cancer	0.000968	0.00306	CcSEcCtD
Mivacurium—Immune system disorder—Paclitaxel—lung cancer	0.000964	0.00304	CcSEcCtD
Mivacurium—Mediastinal disorder—Paclitaxel—lung cancer	0.000962	0.00304	CcSEcCtD
Mivacurium—Arrhythmia—Paclitaxel—lung cancer	0.000954	0.00301	CcSEcCtD
Mivacurium—Phlebitis—Doxorubicin—lung cancer	0.000947	0.00299	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.000938	0.00296	CcSEcCtD
Mivacurium—Anaphylactic shock—Irinotecan—lung cancer	0.00093	0.00294	CcSEcCtD
Mivacurium—Erythema—Paclitaxel—lung cancer	0.000929	0.00293	CcSEcCtD
Mivacurium—Muscle spasms—Etoposide—lung cancer	0.000911	0.00288	CcSEcCtD
Mivacurium—Anaphylactic shock—Gemcitabine—lung cancer	0.000906	0.00286	CcSEcCtD
Mivacurium—Dizziness—Vinblastine—lung cancer	0.000897	0.00283	CcSEcCtD
Mivacurium—Urticaria—Vinorelbine—lung cancer	0.000896	0.00283	CcSEcCtD
Mivacurium—Muscle spasms—Paclitaxel—lung cancer	0.000893	0.00282	CcSEcCtD
Mivacurium—Skin disorder—Gemcitabine—lung cancer	0.00088	0.00278	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000875	0.00276	CcSEcCtD
Mivacurium—Dizziness—Topotecan—lung cancer	0.000872	0.00275	CcSEcCtD
Mivacurium—Hypotension—Irinotecan—lung cancer	0.000869	0.00274	CcSEcCtD
Mivacurium—Dizziness—Erlotinib—lung cancer	0.000862	0.00272	CcSEcCtD
Mivacurium—Hypotension—Gemcitabine—lung cancer	0.000846	0.00267	CcSEcCtD
Mivacurium—Anaphylactic shock—Cisplatin—lung cancer	0.000844	0.00267	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Doxorubicin—lung cancer	0.000843	0.00266	CcSEcCtD
Mivacurium—Flushing—Docetaxel—lung cancer	0.00084	0.00265	CcSEcCtD
Mivacurium—Cardiac disorder—Docetaxel—lung cancer	0.00084	0.00265	CcSEcCtD
Mivacurium—Rash—Topotecan—lung cancer	0.000831	0.00262	CcSEcCtD
Mivacurium—Dermatitis—Topotecan—lung cancer	0.00083	0.00262	CcSEcCtD
Mivacurium—Tachycardia—Cisplatin—lung cancer	0.000824	0.0026	CcSEcCtD
Mivacurium—Rash—Erlotinib—lung cancer	0.000822	0.0026	CcSEcCtD
Mivacurium—Dermatitis—Erlotinib—lung cancer	0.000821	0.00259	CcSEcCtD
Mivacurium—Angiopathy—Docetaxel—lung cancer	0.000821	0.00259	CcSEcCtD
Mivacurium—Skin disorder—Cisplatin—lung cancer	0.00082	0.00259	CcSEcCtD
Mivacurium—Immune system disorder—Docetaxel—lung cancer	0.000817	0.00258	CcSEcCtD
Mivacurium—Mediastinal disorder—Docetaxel—lung cancer	0.000815	0.00257	CcSEcCtD
Mivacurium—Arrhythmia—Docetaxel—lung cancer	0.000808	0.00255	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000801	0.00253	CcSEcCtD
Mivacurium—Hypotension—Cisplatin—lung cancer	0.000789	0.00249	CcSEcCtD
Mivacurium—Erythema—Docetaxel—lung cancer	0.000788	0.00249	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000786	0.00248	CcSEcCtD
Mivacurium—Anaphylactic shock—Etoposide—lung cancer	0.000773	0.00244	CcSEcCtD
Mivacurium—Anaphylactic shock—Paclitaxel—lung cancer	0.000758	0.00239	CcSEcCtD
Mivacurium—Muscle spasms—Docetaxel—lung cancer	0.000757	0.00239	CcSEcCtD
Mivacurium—Tachycardia—Etoposide—lung cancer	0.000755	0.00238	CcSEcCtD
Mivacurium—Skin disorder—Etoposide—lung cancer	0.000751	0.00237	CcSEcCtD
Mivacurium—Dizziness—Vinorelbine—lung cancer	0.000746	0.00235	CcSEcCtD
Mivacurium—Tachycardia—Paclitaxel—lung cancer	0.00074	0.00234	CcSEcCtD
Mivacurium—Skin disorder—Paclitaxel—lung cancer	0.000737	0.00233	CcSEcCtD
Mivacurium—Hypotension—Etoposide—lung cancer	0.000723	0.00228	CcSEcCtD
Mivacurium—Rash—Vinorelbine—lung cancer	0.000711	0.00224	CcSEcCtD
Mivacurium—Dermatitis—Vinorelbine—lung cancer	0.00071	0.00224	CcSEcCtD
Mivacurium—Hypotension—Paclitaxel—lung cancer	0.000709	0.00224	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000666	0.0021	CcSEcCtD
Mivacurium—Anaphylactic shock—Docetaxel—lung cancer	0.000643	0.00203	CcSEcCtD
Mivacurium—Tachycardia—Docetaxel—lung cancer	0.000627	0.00198	CcSEcCtD
Mivacurium—Skin disorder—Docetaxel—lung cancer	0.000624	0.00197	CcSEcCtD
Mivacurium—Dizziness—Irinotecan—lung cancer	0.000615	0.00194	CcSEcCtD
Mivacurium—Urticaria—Etoposide—lung cancer	0.000614	0.00194	CcSEcCtD
Mivacurium—Cardiac disorder—Methotrexate—lung cancer	0.000605	0.00191	CcSEcCtD
Mivacurium—Urticaria—Paclitaxel—lung cancer	0.000602	0.0019	CcSEcCtD
Mivacurium—Hypotension—Docetaxel—lung cancer	0.000601	0.0019	CcSEcCtD
Mivacurium—Angiopathy—Methotrexate—lung cancer	0.000592	0.00187	CcSEcCtD
Mivacurium—Immune system disorder—Methotrexate—lung cancer	0.000589	0.00186	CcSEcCtD
Mivacurium—Mediastinal disorder—Methotrexate—lung cancer	0.000588	0.00186	CcSEcCtD
Mivacurium—Rash—Irinotecan—lung cancer	0.000586	0.00185	CcSEcCtD
Mivacurium—Dermatitis—Irinotecan—lung cancer	0.000586	0.00185	CcSEcCtD
Mivacurium—Bradycardia—Doxorubicin—lung cancer	0.000575	0.00182	CcSEcCtD
Mivacurium—Rash—Gemcitabine—lung cancer	0.000571	0.0018	CcSEcCtD
Mivacurium—Dermatitis—Gemcitabine—lung cancer	0.000571	0.0018	CcSEcCtD
Mivacurium—Erythema—Methotrexate—lung cancer	0.000568	0.00179	CcSEcCtD
Mivacurium—Rash—Cisplatin—lung cancer	0.000532	0.00168	CcSEcCtD
Mivacurium—Dermatitis—Cisplatin—lung cancer	0.000532	0.00168	CcSEcCtD
Mivacurium—Flushing—Doxorubicin—lung cancer	0.000524	0.00165	CcSEcCtD
Mivacurium—Cardiac disorder—Doxorubicin—lung cancer	0.000524	0.00165	CcSEcCtD
Mivacurium—Angiopathy—Doxorubicin—lung cancer	0.000512	0.00162	CcSEcCtD
Mivacurium—Dizziness—Etoposide—lung cancer	0.000511	0.00162	CcSEcCtD
Mivacurium—Immune system disorder—Doxorubicin—lung cancer	0.00051	0.00161	CcSEcCtD
Mivacurium—Mediastinal disorder—Doxorubicin—lung cancer	0.000509	0.00161	CcSEcCtD
Mivacurium—Arrhythmia—Doxorubicin—lung cancer	0.000504	0.00159	CcSEcCtD
Mivacurium—Dizziness—Paclitaxel—lung cancer	0.000501	0.00158	CcSEcCtD
Mivacurium—Erythema—Doxorubicin—lung cancer	0.000492	0.00155	CcSEcCtD
Mivacurium—Rash—Etoposide—lung cancer	0.000488	0.00154	CcSEcCtD
Mivacurium—Dermatitis—Etoposide—lung cancer	0.000487	0.00154	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.00048	0.00152	CcSEcCtD
Mivacurium—Rash—Paclitaxel—lung cancer	0.000478	0.00151	CcSEcCtD
Mivacurium—Dermatitis—Paclitaxel—lung cancer	0.000478	0.00151	CcSEcCtD
Mivacurium—Muscle spasms—Doxorubicin—lung cancer	0.000473	0.00149	CcSEcCtD
Mivacurium—Anaphylactic shock—Methotrexate—lung cancer	0.000463	0.00146	CcSEcCtD
Mivacurium—Skin disorder—Methotrexate—lung cancer	0.00045	0.00142	CcSEcCtD
Mivacurium—Hypotension—Methotrexate—lung cancer	0.000433	0.00137	CcSEcCtD
Mivacurium—Dizziness—Docetaxel—lung cancer	0.000425	0.00134	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000416	0.00131	CcSEcCtD
Mivacurium—Rash—Docetaxel—lung cancer	0.000405	0.00128	CcSEcCtD
Mivacurium—Dermatitis—Docetaxel—lung cancer	0.000405	0.00128	CcSEcCtD
Mivacurium—Anaphylactic shock—Doxorubicin—lung cancer	0.000401	0.00127	CcSEcCtD
Mivacurium—Tachycardia—Doxorubicin—lung cancer	0.000392	0.00124	CcSEcCtD
Mivacurium—Skin disorder—Doxorubicin—lung cancer	0.00039	0.00123	CcSEcCtD
Mivacurium—Hypotension—Doxorubicin—lung cancer	0.000375	0.00118	CcSEcCtD
Mivacurium—Urticaria—Methotrexate—lung cancer	0.000368	0.00116	CcSEcCtD
Mivacurium—Urticaria—Doxorubicin—lung cancer	0.000319	0.00101	CcSEcCtD
Mivacurium—Dizziness—Methotrexate—lung cancer	0.000306	0.000967	CcSEcCtD
Mivacurium—Rash—Methotrexate—lung cancer	0.000292	0.000922	CcSEcCtD
Mivacurium—Dermatitis—Methotrexate—lung cancer	0.000292	0.000922	CcSEcCtD
Mivacurium—Dizziness—Doxorubicin—lung cancer	0.000265	0.000838	CcSEcCtD
Mivacurium—Rash—Doxorubicin—lung cancer	0.000253	0.000799	CcSEcCtD
Mivacurium—Dermatitis—Doxorubicin—lung cancer	0.000253	0.000798	CcSEcCtD
Mivacurium—CHRM3—Metabolism—NCOA3—lung cancer	4.46e-05	0.00012	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—NQO1—lung cancer	4.46e-05	0.00012	CbGpPWpGaD
Mivacurium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—lung cancer	4.46e-05	0.00012	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PXN—lung cancer	4.4e-05	0.000118	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	4.37e-05	0.000117	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of proteins—MMP2—lung cancer	4.36e-05	0.000117	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PXN—lung cancer	4.36e-05	0.000117	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—AVP—lung cancer	4.36e-05	0.000117	CbGpPWpGaD
Mivacurium—BCHE—Neuronal System—HRAS—lung cancer	4.36e-05	0.000117	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ADCY1—lung cancer	4.34e-05	0.000117	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ABCG2—lung cancer	4.34e-05	0.000117	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	4.33e-05	0.000116	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—AVP—lung cancer	4.31e-05	0.000116	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—OXTR—lung cancer	4.31e-05	0.000116	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—GRP—lung cancer	4.31e-05	0.000116	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AKR1C1—lung cancer	4.31e-05	0.000116	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—OXTR—lung cancer	4.27e-05	0.000115	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AKR1C1—lung cancer	4.27e-05	0.000115	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—GRP—lung cancer	4.27e-05	0.000115	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—HPGDS—lung cancer	4.25e-05	0.000114	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ENO2—lung cancer	4.25e-05	0.000114	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PPP2R1B—lung cancer	4.23e-05	0.000114	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—GSTT1—lung cancer	4.13e-05	0.000111	CbGpPWpGaD
Mivacurium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—lung cancer	4.13e-05	0.000111	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—GCLC—lung cancer	4.08e-05	0.00011	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP2A6—lung cancer	4.08e-05	0.00011	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—GNG11—lung cancer	4.03e-05	0.000108	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—STK11—lung cancer	4.02e-05	0.000108	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—GNG11—lung cancer	3.99e-05	0.000107	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—CXCL8—lung cancer	3.96e-05	0.000107	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—AVP—lung cancer	3.96e-05	0.000106	CbGpPWpGaD
Mivacurium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—lung cancer	3.95e-05	0.000106	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—CXCL8—lung cancer	3.92e-05	0.000106	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—AVP—lung cancer	3.92e-05	0.000105	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ENO1—lung cancer	3.87e-05	0.000104	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—VEGFC—lung cancer	3.84e-05	0.000103	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—VEGFC—lung cancer	3.8e-05	0.000102	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of lipids and lipoproteins—PTEN—lung cancer	3.77e-05	0.000101	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—GSTP1—lung cancer	3.72e-05	0.0001	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ADCY1—lung cancer	3.63e-05	9.75e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of proteins—CXCL8—lung cancer	3.63e-05	9.75e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CAT—lung cancer	3.62e-05	9.73e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of lipids and lipoproteins—EP300—lung cancer	3.6e-05	9.67e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ADCY1—lung cancer	3.59e-05	9.66e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PPP2R1B—lung cancer	3.53e-05	9.5e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—SMARCA4—lung cancer	3.53e-05	9.5e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—ABCB1—lung cancer	3.52e-05	9.46e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PPP2R1B—lung cancer	3.5e-05	9.41e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—SMARCA4—lung cancer	3.5e-05	9.41e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP2E1—lung cancer	3.47e-05	9.32e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—TYMS—lung cancer	3.46e-05	9.3e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—NQO1—lung cancer	3.43e-05	9.22e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—GSTM1—lung cancer	3.42e-05	9.19e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HSPB1—lung cancer	3.41e-05	9.17e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HSPB1—lung cancer	3.38e-05	9.08e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PTHLH—lung cancer	3.37e-05	9.07e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PTHLH—lung cancer	3.34e-05	8.98e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CYP1A1—lung cancer	3.24e-05	8.71e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—ERCC2—lung cancer	3.21e-05	8.64e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ANXA1—lung cancer	3.17e-05	8.52e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ANXA1—lung cancer	3.14e-05	8.44e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—STK11—lung cancer	3.09e-05	8.31e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—FLT1—lung cancer	3.07e-05	8.25e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—PIK3CG—lung cancer	3.04e-05	8.18e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—FLT1—lung cancer	3.04e-05	8.17e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—PIK3CG—lung cancer	3.01e-05	8.1e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—APP—lung cancer	3.01e-05	8.08e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NOTCH3—lung cancer	3.01e-05	8.08e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—FGF9—lung cancer	2.98e-05	8.01e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—APP—lung cancer	2.98e-05	8e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NOTCH3—lung cancer	2.98e-05	8e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—FGF9—lung cancer	2.95e-05	7.94e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—POMC—lung cancer	2.9e-05	7.78e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—POMC—lung cancer	2.87e-05	7.71e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—GSTP1—lung cancer	2.86e-05	7.69e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—JUNB—lung cancer	2.85e-05	7.65e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—JUNB—lung cancer	2.82e-05	7.58e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CAT—lung cancer	2.78e-05	7.48e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—APOA1—lung cancer	2.78e-05	7.47e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PIK3CG—lung cancer	2.76e-05	7.43e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PIK3CG—lung cancer	2.74e-05	7.35e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ABCB1—lung cancer	2.71e-05	7.28e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—PIK3CD—lung cancer	2.67e-05	7.19e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.66e-05	7.16e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—TYMS—lung cancer	2.66e-05	7.15e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—PIK3CD—lung cancer	2.65e-05	7.12e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—POMC—lung cancer	2.63e-05	7.07e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—GSTM1—lung cancer	2.63e-05	7.07e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—POMC—lung cancer	2.6e-05	7e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—STK11—lung cancer	2.58e-05	6.95e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—IL6R—lung cancer	2.56e-05	6.9e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—STK11—lung cancer	2.56e-05	6.88e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—IL6R—lung cancer	2.54e-05	6.83e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PIK3CG—lung cancer	2.54e-05	6.82e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—FOXO3—lung cancer	2.49e-05	6.71e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP1A1—lung cancer	2.49e-05	6.7e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ERCC2—lung cancer	2.47e-05	6.64e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—FOXO3—lung cancer	2.47e-05	6.64e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—MAP2K1—lung cancer	2.44e-05	6.57e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PIK3CD—lung cancer	2.43e-05	6.53e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—MAP2K1—lung cancer	2.42e-05	6.51e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—POMC—lung cancer	2.42e-05	6.49e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PIK3CD—lung cancer	2.4e-05	6.47e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CREBBP—lung cancer	2.35e-05	6.33e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AVP—lung cancer	2.34e-05	6.28e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—PIK3CB—lung cancer	2.33e-05	6.27e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AVP—lung cancer	2.31e-05	6.22e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—PIK3CB—lung cancer	2.31e-05	6.21e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IGF1R—lung cancer	2.25e-05	6.05e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—CXCL8—lung cancer	2.24e-05	6.02e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PIK3CD—lung cancer	2.23e-05	6e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IGF1R—lung cancer	2.23e-05	5.99e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—CXCL8—lung cancer	2.22e-05	5.96e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HES1—lung cancer	2.21e-05	5.94e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—ALB—lung cancer	2.2e-05	5.92e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HES1—lung cancer	2.19e-05	5.88e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—RAF1—lung cancer	2.17e-05	5.83e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—RAF1—lung cancer	2.15e-05	5.77e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—IL2—lung cancer	2.14e-05	5.75e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—APOA1—lung cancer	2.14e-05	5.75e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—IL2—lung cancer	2.12e-05	5.7e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PIK3CB—lung cancer	2.12e-05	5.69e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PIK3CB—lung cancer	2.1e-05	5.64e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—CXCL8—lung cancer	2.03e-05	5.47e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ERBB3—lung cancer	2.02e-05	5.43e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—CXCL8—lung cancer	2.01e-05	5.42e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ERBB3—lung cancer	2e-05	5.38e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PIK3CG—lung cancer	1.95e-05	5.25e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PIK3CB—lung cancer	1.94e-05	5.23e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—IL2—lung cancer	1.94e-05	5.23e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TERT—lung cancer	1.94e-05	5.21e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PTGS2—lung cancer	1.93e-05	5.18e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—IL2—lung cancer	1.92e-05	5.18e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TERT—lung cancer	1.92e-05	5.16e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—FGFR1—lung cancer	1.88e-05	5.06e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—FGFR1—lung cancer	1.86e-05	5.01e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—POMC—lung cancer	1.86e-05	4.99e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HIF1A—lung cancer	1.85e-05	4.98e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HIF1A—lung cancer	1.83e-05	4.93e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CREBBP—lung cancer	1.81e-05	4.86e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—APOA1—lung cancer	1.79e-05	4.81e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—KDR—lung cancer	1.77e-05	4.76e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—APOA1—lung cancer	1.77e-05	4.76e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—KDR—lung cancer	1.75e-05	4.72e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PIK3CD—lung cancer	1.72e-05	4.61e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ALB—lung cancer	1.69e-05	4.55e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PTEN—lung cancer	1.68e-05	4.52e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—APC—lung cancer	1.63e-05	4.39e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PIK3CG—lung cancer	1.63e-05	4.39e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—KIT—lung cancer	1.63e-05	4.39e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—NRAS—lung cancer	1.63e-05	4.39e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—APC—lung cancer	1.62e-05	4.34e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—KIT—lung cancer	1.62e-05	4.34e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PIK3CG—lung cancer	1.62e-05	4.34e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—NRAS—lung cancer	1.62e-05	4.34e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—EGF—lung cancer	1.61e-05	4.34e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—EP300—lung cancer	1.6e-05	4.31e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—EGF—lung cancer	1.6e-05	4.29e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—MAPK3—lung cancer	1.56e-05	4.2e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—POMC—lung cancer	1.55e-05	4.18e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—MAPK3—lung cancer	1.55e-05	4.16e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—POMC—lung cancer	1.54e-05	4.14e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—BRAF—lung cancer	1.53e-05	4.12e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—BRAF—lung cancer	1.52e-05	4.08e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IL6R—lung cancer	1.52e-05	4.07e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CREBBP—lung cancer	1.51e-05	4.07e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IL6R—lung cancer	1.5e-05	4.03e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CREBBP—lung cancer	1.5e-05	4.03e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PIK3CB—lung cancer	1.5e-05	4.02e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—EGFR—lung cancer	1.49e-05	4e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PTGS2—lung cancer	1.48e-05	3.98e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—EGFR—lung cancer	1.47e-05	3.96e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MAP2K1—lung cancer	1.44e-05	3.88e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PIK3CD—lung cancer	1.43e-05	3.86e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MAP2K1—lung cancer	1.43e-05	3.84e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—PIK3CA—lung cancer	1.42e-05	3.82e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PIK3CD—lung cancer	1.42e-05	3.82e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—PIK3CA—lung cancer	1.41e-05	3.78e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—KRAS—lung cancer	1.4e-05	3.78e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—KRAS—lung cancer	1.39e-05	3.74e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PTEN—lung cancer	1.29e-05	3.47e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PIK3CA—lung cancer	1.29e-05	3.47e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MDM2—lung cancer	1.29e-05	3.45e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—RAF1—lung cancer	1.28e-05	3.44e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PIK3CA—lung cancer	1.28e-05	3.44e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MDM2—lung cancer	1.27e-05	3.42e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—RAF1—lung cancer	1.27e-05	3.41e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ERBB2—lung cancer	1.27e-05	3.41e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ERBB2—lung cancer	1.25e-05	3.37e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MTOR—lung cancer	1.25e-05	3.36e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PIK3CB—lung cancer	1.25e-05	3.36e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MTOR—lung cancer	1.24e-05	3.33e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PIK3CB—lung cancer	1.24e-05	3.33e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—EP300—lung cancer	1.23e-05	3.31e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CXCL8—lung cancer	1.2e-05	3.23e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—HRAS—lung cancer	1.19e-05	3.21e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CXCL8—lung cancer	1.19e-05	3.2e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PIK3CA—lung cancer	1.19e-05	3.19e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—HRAS—lung cancer	1.18e-05	3.18e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—AKT1—lung cancer	1.16e-05	3.12e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CASP3—lung cancer	1.15e-05	3.09e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—AKT1—lung cancer	1.15e-05	3.09e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IL2—lung cancer	1.15e-05	3.09e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—IL6—lung cancer	1.14e-05	3.07e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CASP3—lung cancer	1.14e-05	3.06e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IL2—lung cancer	1.14e-05	3.06e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—IL6—lung cancer	1.13e-05	3.04e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CCND1—lung cancer	1.12e-05	3.01e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—JUN—lung cancer	1.12e-05	3e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CCND1—lung cancer	1.11e-05	2.98e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—JUN—lung cancer	1.11e-05	2.97e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MMP9—lung cancer	1.09e-05	2.92e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CDKN1A—lung cancer	1.08e-05	2.91e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PTEN—lung cancer	1.08e-05	2.9e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MMP9—lung cancer	1.08e-05	2.89e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CDKN1A—lung cancer	1.07e-05	2.88e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PTEN—lung cancer	1.07e-05	2.88e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—AKT1—lung cancer	1.05e-05	2.83e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—AKT1—lung cancer	1.04e-05	2.81e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—EP300—lung cancer	1.03e-05	2.77e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—EP300—lung cancer	1.02e-05	2.74e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—SRC—lung cancer	1e-05	2.69e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—SRC—lung cancer	9.92e-06	2.67e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—VEGFA—lung cancer	9.76e-06	2.62e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—AKT1—lung cancer	9.68e-06	2.6e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—VEGFA—lung cancer	9.66e-06	2.6e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—STAT3—lung cancer	9.66e-06	2.6e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NRAS—lung cancer	9.64e-06	2.59e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—STAT3—lung cancer	9.57e-06	2.57e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NRAS—lung cancer	9.55e-06	2.57e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MAPK3—lung cancer	9.23e-06	2.48e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MAPK3—lung cancer	9.14e-06	2.46e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PIK3CA—lung cancer	9.12e-06	2.45e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MYC—lung cancer	8.98e-06	2.41e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MYC—lung cancer	8.89e-06	2.39e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—EGFR—lung cancer	8.78e-06	2.36e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—EGFR—lung cancer	8.7e-06	2.34e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—KRAS—lung cancer	8.3e-06	2.23e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—KRAS—lung cancer	8.22e-06	2.21e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PIK3CA—lung cancer	7.62e-06	2.05e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PIK3CA—lung cancer	7.55e-06	2.03e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—AKT1—lung cancer	7.45e-06	2e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TP53—lung cancer	7.37e-06	1.98e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TP53—lung cancer	7.3e-06	1.96e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HRAS—lung cancer	7.05e-06	1.9e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HRAS—lung cancer	6.98e-06	1.88e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IL6—lung cancer	6.75e-06	1.81e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IL6—lung cancer	6.68e-06	1.8e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AKT1—lung cancer	6.23e-06	1.67e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AKT1—lung cancer	6.17e-06	1.66e-05	CbGpPWpGaD
